Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee.
about
Malignant pleural mesothelioma: predictors and stagingClinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy.Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural MesotheliomaValidation of EORTC and CALGB prognostic models in surgical patients submitted to diagnostic, palliative or curative surgery for malignant pleural mesothelioma.Investigating palygorskite's role in the development of mesothelioma in southern Nevada: Insights into fiber-induced carcinogenicityPlasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.The effects of an intentional transition from extrapleural pneumonectomy to extended pleurectomy/decortication.Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis.Clinical staging of malignant pleural mesothelioma: current perspectives.Extended pleurectomy decortication for malignant pleural mesothelioma in the elderly: the need for an inclusive yet selective approach.A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients.Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography?The management of the diaphragm during radical surgery for malignant pleural mesothelioma.Malignant pleural mesothelioma-the impact of globalization on rare diseases.Extended pleurectomy decortication: the current role
P2860
Q33871571-FA7406B1-30AC-4374-BB7B-07764C9F441EQ36345736-B3A46CC2-0AFA-41BA-863C-7DE144785840Q37029331-BC8E8DE5-CE0B-49CE-BCE9-9BF3E2C879EAQ37208731-F1CE1A97-D498-40FA-A65E-195A786C1140Q37335386-D55F2F60-7D2C-4554-9231-53E047E40E8DQ39977787-6D1C4958-7172-41F7-9396-7CD0F4639751Q40242222-02E3FF8F-5113-4C92-9576-94AC8E7ED9C9Q41234207-07F85B80-90FE-4957-AC72-B5B82073D191Q41522440-5B489ABE-8568-4F26-AFA2-546781F90465Q47759752-D94F501B-D555-4B54-AF30-E38199CB13E7Q51643878-854C632A-6B21-4917-BF00-0FFE8F5D0C18Q52590080-4D8F2AF3-BBC6-4081-9FD2-B03BD9AD0612Q52610273-59D4A6E7-FAA5-4E0B-9B4C-F0A0EB5E2B2DQ52878999-0349CAD9-72E1-4176-AE07-FA177EBD50DBQ55172221-3384F2DA-9154-4DD0-803E-A974EE4ACE21Q59137558-9088369D-503D-495D-AEBA-4EC3D2C59710
P2860
Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Supplementary prognostic varia ...... m the IASLC staging committee.
@ast
Supplementary prognostic varia ...... m the IASLC staging committee.
@en
Supplementary prognostic varia ...... m the IASLC staging committee.
@nl
type
label
Supplementary prognostic varia ...... m the IASLC staging committee.
@ast
Supplementary prognostic varia ...... m the IASLC staging committee.
@en
Supplementary prognostic varia ...... m the IASLC staging committee.
@nl
prefLabel
Supplementary prognostic varia ...... m the IASLC staging committee.
@ast
Supplementary prognostic varia ...... m the IASLC staging committee.
@en
Supplementary prognostic varia ...... m the IASLC staging committee.
@nl
P2093
P2860
P50
P1476
Supplementary prognostic varia ...... om the IASLC staging committee
@en
P2093
Ayten K Cangir
Catherine Kennedy
David Rice
David Waller
Dorothy Giroux
Hans Hoffmann
Hisao Asamura
IASLC Staging Committee and Participating Institutions
Jan P van Meerbeeck
John Edwards
P2860
P304
P356
10.1097/JTO.0000000000000181
P577
2014-06-01T00:00:00Z